# Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Source: https://onco.cc/trials/nct05086614/  
OnCo record `nct05086614` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Fudan University, now recruiting.

## Summary

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer is a phase 3, randomised interventional study registered as NCT05086614 by Fudan University, with a registry enrolment figure of 2500 participants, started 2021-04-01 and due to reach its primary completion in 2027-03-31. Interventions recorded: Thymosin Alpha1. Conditions listed: Stage II Colorectal Cancer; Stage III Colorectal Cancer. Primary outcome: 3-year disease-free survival rate. Colorectal eligibility wording from the registry: "* Colorectal cancer receiving radical resection". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05086614
- Phase: 3
- Setting: The Efficacy and Safety of Thymosin-alpha 1 Used for Adjuvant Treatment After Radical Resection of High-risk Stage II and Stage III Colorectal Cancer
- Sponsor: Fudan University
- Enrolled: 2500

## Sources

- ClinicalTrials.gov NCT05086614: https://clinicaltrials.gov/study/NCT05086614

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05086614.json